These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 34992090)

  • 1. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
    Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
    Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
    Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
    Laengle J; Kabiljo J; Hunter L; Homola J; Prodinger S; Egger G; Bergmann M
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
    Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
    J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Margetuximab in HER2-positive metastatic breast cancer.
    Gradishar WJ; O'Regan R; Rimawi MF; Nordstrom JL; Rosales MK; Rugo HS
    Future Oncol; 2023 May; 19(16):1099-1112. PubMed ID: 37170847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
    Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
    J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
    J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity.
    Jung ST; Kelton W; Kang TH; Ng DT; Andersen JT; Sandlie I; Sarkar CA; Georgiou G
    ACS Chem Biol; 2013 Feb; 8(2):368-75. PubMed ID: 23030766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
    Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
    Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge variant analysis of proposed biosimilar to Trastuzumab.
    Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
    Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.
    Tsao LC; Crosby EJ; Trotter TN; Agarwal P; Hwang BJ; Acharya C; Shuptrine CW; Wang T; Wei J; Yang X; Lei G; Liu CX; Rabiola CA; Chodosh LA; Muller WJ; Lyerly HK; Hartman ZC
    JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31689243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.
    Alasmari MM
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.